POMC and cancer: Patients with cancer receiving therapies known to potentially cause HPA hypofunction such as cerebral or nasopharyngeal irradiation, immune checkpoint inhibitors or mitotane should be systematically screened with morning serum cortisol and adrenocorticotrophin (ACTH) measurements, alone or in combination with a short Synacthen test.